Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution

The Foundation for Orthopaedics and Regenerative Medicine18 enrolled

Overview

Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.

Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Motor Disorders

Interventions

AlloEx exosomesBIOLOGICAL

This is an intranasal treatment of exosomes derived from mesenchymal stem cells.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients will need a diagnosis established by a neurologist. Patients must be able to provide informed consent, or have a guardian who does. They must be able to travel to the site of treatment. Exclusion Criteria: * Patients were excluded from the trial if they were pregnant or had active cancer at the screening consultation.

Locations (1)

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Outcomes

Primary Outcomes

ALSFRS-R Results

Time frame: from enrollment until 6 months after treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.